MGTX Stock — MeiraGTx Holdings plc: Cash, EV, Pipeline

What they do

We are a vertically integrated, clinical-stage genetic medicines company with a broad pipeline of late-stage clinical programs, including radiation-induced xerostomia, Parkinson’s disease and AIPL1-associated retinal dystrophy. Our clinical programs use targeted local delivery of small doses of genetic medicines to treat both inherited and more common conditions with severe unmet need.

Source: 10-K FY2025 via SEC EDGAR

Share price

$9.24

Market cap

$903.1M

Cash

$184.7M

Enterprise value

$718.5M

Balance sheet

Cash	$184.7M
Debt	$0.0M
Net cash	$184.7M
Enterprise value	$718.5M
Basic shares	97.7M shares
Fully diluted shares	105.3M shares
Fully diluted market cap	$972.8M
Cash per share	$1.89
Quarterly burn	$38.5M
Cash runway	3.7 quarters

Cash figures as of 2026-09-30. Database snapshot: 2026-11-13.

Share structure

Common

96.0M

Pre-funded warrants

0.0M

Options

4.7M

RSUs

0.0M

Warrants

0.7M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

3.8M

FDSO

105.3M

Cap table as of 2026-06-30.

Price history

Loading MGTX daily closes…

Loading price history…

Next catalyst

Bota-vec · Est. Nov 14, 2026 · guidance midpoint · guided Now

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
GUIDEDEst. Nov 14, 2026 Now guidance midpoint	Bota-vec Global regulatory filings in X-linked retinitis pigmentosa	Not disclosed	X-linked retinitis pigmentosa	2026
Jul 13 - Aug 24 in 8 mo	AAV2-hAQP1 Concentration 1	Phase 2	Grade 2 and 3 Late Xerostomia Caused by Radiotherapy for Cancers of th	End 2027 (BLA filing and potential approval, if AQUAx2 positive)
Nov 12 - Dec 24 in 36 mo	AAV-GAD	Phase 1/2	Parkinson's Disease	—
Mar 14 - Apr 25 in 65 mo	AAV2-hAQP1	Phase 2	Grade 2 and 3 Late Xerostomia Caused by Radiotherapy for Cancers of th	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

AAV-GAD

Phase 1 · Active Modality: Gene therapy (one-time bilateral subthalamic-nucleus infusion)

Target GAD (glutamic acid decarboxylase)

Partnerships Hologen (Mar 2025 strategic collaboration via Reogen joint venture): $200M upfront + up to $230M to fund AAV-GAD development to commercialization; uses Hologen AI on trial data; company manufactures/supplies drug product

Indications

Parkinson's disease (Phase 1)

Status note Phase 1 bridging study MGT-GAD-025 (14 pts, commercial platform process) completed; data announced Oct 2024. FDA RMAT designation granted May 2025 for Parkinson's disease not adequately controlled with anti-Parkinsonian medications. Hologen collaboration funded to advance to commercialization.

AAV-BDNF

Stage not disclosed · Active Modality: Gene therapy (local CNS delivery)

Target BDNF

Partnerships Hologen / Reogen joint venture (Clinical Programs); company manufactures/supplies

Indications

Genetic obesity disorders (Stage not disclosed)

Status note Investigational gene therapy for genetic obesity disorders, one of the CNS Clinical Programs under the Hologen/Reogen collaboration. 10-Q does not state trial phase.

AAV-AIPL1

Stage not disclosed · Active Modality: Gene therapy (subretinal rAAV8.hRKp.AIPL1)

Target AIPL1

Partnerships Eli Lilly (Nov 2025 strategic collaboration and license): exclusive worldwide rights to research, develop and commercialize AAV-AIPL1, plus two other preclinical IRD candidates, intravitreal capsids/promoters licenses, ophthalmology right of first designation

Indications

Leber congenital amaurosis 4 (AIPL1 gene mutations) (Stage not disclosed)

Status note AAV-AIPL1 manufactured/released for compassionate use (MHRA specials license, UK; 11 children). First-in-human interventional study published in The Lancet (Feb 2025). No phase stated in the 10-Q.

AAV-CNGB3

Phase 1/2 · Active Modality: Gene therapy

Target CNGB3

Indications

Achromatopsia (CNGB3 mutations) (Phase 1/2)

Status note One of three Phase 1/2 IRD programs the company may develop itself or with a strategic partner.

AAV-CNGA3

Phase 1/2 · Active Modality: Gene therapy

Target CNGA3

Indications

Achromatopsia (CNGA3 mutations) (Phase 1/2)

Status note One of three Phase 1/2 IRD programs the company may develop itself or with a strategic partner.

AAV-RPE65

Phase 1/2 · Active Modality: Gene therapy

Target RPE65

Indications

Retinal dystrophy (RPE65 deficiency) (Phase 1/2)

Status note One of three Phase 1/2 IRD programs the company may develop itself or with a strategic partner.

AAV-BBS10

Stage not disclosed · Active Modality: Gene therapy

Target BBS10

Indications

Bardet-Biedl syndrome (BBS10 mutations) (Stage not disclosed)

Status note Manufactured and released for compassionate use (MHRA specials license, UK). No phase stated in the 10-Q.

Per-asset detail extracted from the 10-Q filed 2026-08-13. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

No lead program on file for this company.

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT05926765	Phase 2	Active, not recruiting	Sponsor	MeiraGTx, LLC	—	Grade 2 and 3 Late Xerostomia Caused by Radiotherapy for Cancers of th	End 2027 (BLA filing and potential approval, if AQUAx2 positive)
NCT06544798	Phase 2	Enrolling by invitation	Sponsor	MeiraGTx, LLC	—	Grade 2 and 3 Late Xerostomia Caused by Radiotherapy for Cancers of th	—
NCT05894343	Phase 1/2	Active, not recruiting	Sponsor	MeiraGTx, LLC	—	Parkinson's Disease	—
NCT05060341	Not disclosed	Active, not recruiting	Sponsor	MeiraGTx, LLC	—	Radiation-induced Xerostomia	—

Sponsor-matched active trials from ClinicalTrials.gov (4 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 4 active trials for MeiraGTx, LLC on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
Perceptive Advisors	10,786,658	+460,555	2.26%	2026-08-14
Logos Global Management	0	-700,000	0.00%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

MGTX — MeiraGTx Holdings plc ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Upcoming catalysts

Pipeline assets

Active clinical trials

Specialist fund holders

Latest news

MGTX — MeiraGTx Holdings plc